Novartis shares have fallen after US regulators said a unit that developed a costly breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it before the treatment was approved.

EIRCOM shares continued their fall from grace yesterday, falling for the third day in a row as Swisscom finally owned up to being behind last week’s takeover approach.